For nearly three decades, triptans were the only migraine-specific acute treatment available. Sumatriptan (Imitrex) hit the market in 1992; six more triptans followed over the next decade. Then nothing new for almost 30 years — until 2020, when the FDA approved the first gepants. The landscape has changed in a meaningful way, and the choice between an old generic and a newer brand-name medication is genuinely worth thinking about.

How they actually work

Both classes target the same underlying biology of migraine, but at different points.

Triptans (sumatriptan, rizatriptan, eletriptan, etc.) are serotonin (5-HT1B/1D) receptor agonists. They work in two ways: they cause cerebral blood vessels to constrict (reversing the dilation that happens during a migraine), and they block the release of inflammatory neuropeptides from trigeminal nerves. The vasoconstriction is part of why they work — and also why they’re a problem for some people.

Gepants (ubrogepant/Ubrelvy, rimegepant/Nurtec ODT, zavegepant/Zavzpret) block the CGRP receptor. CGRP (calcitonin gene-related peptide) is a key signaling molecule released during migraine that drives inflammation, pain transmission, and blood vessel dilation. Block the CGRP receptor and you interrupt the migraine cascade without causing vasoconstriction. No vasoconstriction is the key safety advantage.

Effectiveness: triptans usually win head-to-head

In direct comparisons, most triptans outperform the gepants on the standard outcomes used in migraine trials — pain freedom at 2 hours, and significant pain relief at 2 hours. To put rough numbers on it: in trials, rimegepant produced complete pain freedom at 2 hours in around 21% of patients (versus 11% on placebo), and ubrogepant’s numbers are similar. Triptans typically clear that bar in 30 to 40% of patients, sometimes higher with eletriptan.

So if effectiveness is your only criterion and you can take a triptan safely, sumatriptan or one of its cousins is usually the more reliable choice. The gepants are still meaningfully better than placebo — they help a lot of people — just usually less dramatically than triptans for the same person.

Safety: where the gepants pull ahead

The vasoconstriction that helps triptans work also restricts who can use them. Triptans are contraindicated in:

• Coronary artery disease or history of heart attack
• Stroke or transient ischemic attack (TIA) history
• Peripheral vascular disease
• Uncontrolled hypertension
• Hemiplegic or basilar migraine variants
• Pregnancy (relative contraindication — case-by-case)
• Taking certain other medications (MAOIs, ergot derivatives, recent triptan within 24 hours)

These restrictions exclude a meaningful percentage of migraine patients — particularly people over 50, people with a strong family history of cardiovascular disease, and people with multiple risk factors. Gepants don’t cause vasoconstriction, so they’re generally safe in all of these populations. That alone is a substantial reason for their existence.

Side effects also tend to differ:

• Triptan side effects — the classic “triptan sensations”: chest tightness, neck pressure, jaw or shoulder tightness, flushing, tingling, dizziness, fatigue. These are usually transient and not dangerous, but uncomfortable and sometimes alarming.
• Gepant side effects — generally mild. Nausea (5 to 10%), fatigue, dry mouth. No vasoconstrictive sensations.

Other practical differences

• Cost. Generic sumatriptan tablets are often a few dollars per month with discount cards. The gepants are brand-only and expensive — typically $80 to $100+ per dose without good insurance coverage. Manufacturer copay cards can drop commercial-insurance copays to as low as $0; for people on Medicare or Medicaid, those programs aren’t available and the cost is harder to manage.
• Onset speed. Sumatriptan injection works fastest (within 10 to 15 minutes), followed by sumatriptan nasal spray, then oral triptans (30 to 60 minutes). Among gepants, Zavzpret (zavegepant) nasal spray is the fastest, followed by Nurtec ODT (rimegepant) which dissolves on the tongue, then Ubrelvy (ubrogepant) tablets.
• Repeat dosing. Triptans typically allow a second dose 2 hours later if the first didn’t work, with daily limits. Gepants have similar repeat-dosing rules. Neither should be used more than 2 to 3 days per week, or you risk medication-overuse headache.
• Dual use as preventive. Rimegepant (Nurtec ODT) is uniquely approved for both acute treatment and prevention — taken every other day, it can reduce monthly migraine days while still being available for individual attacks. Triptans are acute-only.
• Drug interactions. Triptans and gepants both have important interactions worth checking. Triptans interact with MAOIs and SSRIs (serotonin syndrome risk, often overstated but worth knowing); gepants interact with strong CYP3A4 inhibitors and inducers (ketoconazole, rifampin, certain HIV medications).

When sumatriptan is probably the right pick

• Otherwise-healthy adult without cardiovascular disease, well-controlled hypertension, no stroke history
• Cost is a major factor (sumatriptan generic is the cheapest migraine-specific medication available)
• Severe attacks where the most effective option matters more than tolerability
• Need for fast onset (sumatriptan injection or nasal spray)

When a gepant is probably the right pick

• Cardiovascular disease, stroke history, uncontrolled hypertension, or peripheral vascular disease (gepants are the safer choice)
• Triptans haven’t worked well, or have caused intolerable side effects (chest tightness, jaw pressure, dizziness)
• You’re between occasional and frequent migraines and could benefit from rimegepant’s preventive use
• Your prescriber wants to avoid medication-overuse headache concerns — gepants appear less likely to cause this than triptans
• Severe nausea makes oral medications hard to keep down (Zavzpret nasal spray bypasses that)

A practical workflow

For most patients without cardiovascular issues, the standard approach still starts with a generic triptan (often sumatriptan). It’s cheap, works well for most people, and you find out quickly whether it works for you. If it does, problem largely solved.

If sumatriptan doesn’t work well enough, the next steps depend on the situation: try a different triptan (people often respond differently to different triptans — rizatriptan, eletriptan, and frovatriptan all behave somewhat differently), or move to a gepant. If it works but the side effects are intolerable, gepants are usually the next step.

If you have cardiovascular contraindications, you skip triptans entirely and start with a gepant. Or with lasmiditan (Reyvow), a “ditan” — also serotonin-receptor-targeted but without the vasoconstriction — which is cardiovascular-safe but causes significant drowsiness and driving restrictions. (For most people the gepants are easier to tolerate.)

And for the bigger picture on managing migraine — triggers, prevention, when to escalate care — the article on chronic migraine treatments, triggers, and support covers the broader strategy. If cost is the main issue with whichever medication your prescriber recommends, the post on generic vs brand name medications is worth a read.

References

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678924/
• https://virtualheadachespecialist.com/ubrelvy-vs-nurtec-odt-vs-reyvow-vs-triptans-new-migraine-abortive-options-are-finally-here-but-what-are-the-differences-and-is-one-best-for-you/
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775271/
• https://scienceinsights.org/what-is-the-best-migraine-medicine-for-you/